| A review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis ER Mears, F Modabber, R Don, GE Johnson PLoS neglected tropical diseases 9 (9), e0003889, 2015 | 123 | 2015 |
| Brain urea increase is an early Huntington’s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases RR Handley, SJ Reid, R Brauning, P Maclean, ER Mears, I Fourie, ... Proceedings of the National Academy of Sciences 114 (52), E11293-E11302, 2017 | 92 | 2017 |
| Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection R Ameratunga, K Lehnert, E Leung, D Comoletti, R Snell, ST Woon, ... Open Access Te Herenga Waka-Victoria University of Wellington, 2020 | 29 | 2020 |
| Extensive intraspecies cryptic variation in an ancient embryonic gene regulatory network YN Torres Cleuren, CK Ewe, KC Chipman, ER Mears, CG Wood, ... Elife 8, e48220, 2019 | 24 | 2019 |
| Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari*(modified ACE2) drug treatment project of SARS-CoV-2 infection R Ameratunga, ST Woon, R Steele, R Snell, N Medlicott, E Mears, ... Expert Review of Clinical Immunology 17 (6), 553-560, 2021 | 12 | 2021 |
| A multi-omic Huntington’s disease transgenic sheep-model database for investigating disease pathogenesis ER Mears, RR Handley, MJ Grant, SJ Reid, BT Day, SR Rudiger, ... Journal of Huntington's Disease 10 (4), 423-434, 2021 | 9 | 2021 |
| Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19 R Ameratunga, E Mears, E Leung, R Snell, ST Woon, W Kelton, ... Clinical and Experimental Immunology 214 (3), 289-295, 2023 | 2 | 2023 |
| Successful editing and maintenance of lactogenic gene expression in primary bovine mammary epithelial cells J Moody, E Mears, AJ Trevarton, M Broadhurst, A Molenaar, T Chometon, ... In Vitro Cellular & Developmental Biology-Animal 59 (5), 316-330, 2023 | 2 | 2023 |
| Investigating the Molecular Mechanisms of Huntington's Disease E Mears PhD Thesis-University of Auckland, 2018 | 1 | 2018 |
| SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for … R Ameratunga, A Jordan, K Lehnert, E Leung, ER Mears, R Snell, ... Antiviral Research, 105894, 2024 | | 2024 |
| Development of SpCas9-expressing bovine mammary epithelial cell lines AJ Trevarton, ER Mears, J Moody, TJ Lopdell, TQ Chometon, JA Taylor, ... In Vitro Cellular & Developmental Biology-Animal 59 (3), 163-165, 2023 | | 2023 |
| Reciprocal requirement of Wnt signaling and SKN-1 underlies cryptic intraspecies variation in an ancient embryonic gene regulatory network YN Torres Cleuren, CK Ewe, KC Chipman, E Mears, CG Wood, ... bioRxiv, 628495, 2019 | | 2019 |
